Hogan Lovells advises Vifor Pharma on establishment of joint venture with Evotec for early stage development in nephrology

Press releases | 12 November 2019

Led by Munich partner Michael Rose, Hogan Lovells has advised the Swiss pharmaceutical company Vifor Pharma on the establishment of a joint venture with Evotec focusing on the research and development of novel therapies in the field of nephrology. Hamburg partner Arne Thiermann was in charge of the regulatory and pharmaceutical aspects.

With the joint venture, Vifor Pharma will gain access to external R&D capacities, while Evotec will gain a marketing partner by licensing out the nephrology assets developed within the framework of the joint venture. The joint venture will be used to analyze clinical data provided by Evotec through the analysis of a biological database in order to identify new target structures for the treatment of kidney diseases. 

At Hogan Lovells, Jörg Schickert's team in particular has been working for Vifor Pharma for many years in the context of providing pharmaceutical and contract law advice. 

Hogan Lovells Team for Vifor Pharma Group


Dr. Michael Rose (Partner), Dr. Moritz Maier (Senior Associate), Christopher Hildebrandt (Associate) (all Corporate/ M&A);

Dr. Tina Welter-Birk (Senior Associate, Pharma law);

Dr. Ingmar Dörr (Partner, Tax); 

Matthias Schlau (Associate, Antitrust);


Arne Thiermann (Partner), Simon Schwager (Associate, Pharma law);


Dr. Falk Schöning, (Partner), Dr. Philipp Heuser (Associate) (both Antitrust).